These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33584066)

  • 1. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
    Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
    Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 4. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 5. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
    Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
    Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.
    Liu CJ; Seto WK; Yu ML
    Hepatol Int; 2024 Oct; 18(Suppl 2):897-908. PubMed ID: 39115632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
    Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
    Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.
    Huang CF; Liang PC; Tsai PC; Wei YJ; Huang CI; Wang CW; Jang TY; Yeh ML; Hsu PY; Hsieh MY; Lin YH; Dai CY; Chuang WL; Huang JF; Yu ML
    J Gastroenterol Hepatol; 2024 Jan; 39(1):193-201. PubMed ID: 37731071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.
    Yilmaz B; Koklu S; Buyukbayram H; Yalçin K; Korkmaz U; Posul E; Can G; Kurt M
    Afr Health Sci; 2015 Sep; 15(3):714-8. PubMed ID: 26957957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
    Huang J; Xue W; Wang M; Wu Y; Singh M; Zhu Y; Kumar R; Lin S
    Diabetes Metab Syndr Obes; 2021; 14():3417-3425. PubMed ID: 34349535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
    Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
    Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
    Mi YQ; Liu YG; Xu L; Fan JG; Zhang H; Ping L; Shi RF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):817-20. PubMed ID: 19958639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
    Yang DL; Liu SP; Wang HL; Li JR; Su JY; Li MJ; Teng YX; Deng ZJ; Li ZH; Huang JL; Guo PP; Ma L; Li ZZ; Zhong JH
    Infect Agent Cancer; 2024 May; 19(1):21. PubMed ID: 38693556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
    Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
    Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
    Wu X; Li P; Mi YQ
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.